Factors influencing global antiretroviral procurement prices

Wirtz, Veronika J.; Forsythe, Steven; Valencia-Mendoza, Atanacio; Bautista-Arredondo, Sergio
January 2009
BMC Public Health;2009 Supplement 1, Vol. 9, Special section p1
Academic Journal
Background: Antiretroviral medicines (ARVs) are one of the most costly parts of HIV/AIDS treatment. Many countries are struggling to provide universal access to ARVs for all people living with HIV and AIDS. Although substantial price reductions of ARVs have occurred, especially between 2002 and 2008, achieving sustainable access for the next several decades remains a major challenge for most low- and middle-income countries. The objectives of the present study were twofold: first, to analyze global ARV prices between 2005 and 2008 and associated factors, particularly procurement methods and key donor policies on ARV procurement efficiency; second, to discuss the options of procurement processes and policies that should be considered when implementing or reforming access to ARV programs. Methods: An ARV-medicines price-analysis was carried out using the Global Price Reporting Mechanism from the World Health Organization. For a selection of 12 ARVs, global median prices and price variation were calculated. Linear regression models for each ARV were used to identify factors that were associated with lower procurement prices. Logistic regression models were used to identify the characteristics of those countries which procure below the highest and lowest direct manufactured costs. Results: Three key factors appear to have an influence on a country's ARV prices: (a) whether the product is generic or not; (b) the socioeconomic status of the country; (c) whether the country is a member of the Clinton HIV/AIDS Initiative. Factors which did not influence procurement below the highest direct manufactured costs were HIV prevalence, procurement volume, whether the country belongs to the least developed countries or a focus country of the United States President's Emergency Plan For AIDS Relief. Conclusion: One of the principal mechanisms that can help to lower prices for ARV over the next several decades is increasing procurement efficiency. Benchmarking prices could be one useful tool to achieve this.


Related Articles

  • Clinton brokers deal to lower price of antiretrovirals. Abimbola, Seye // BMJ: British Medical Journal (International Edition);5/19/2007, Vol. 334 Issue 7602, p1026 

    This article reports that former U.S. president Bill Clinton has brokered a deal to provide cheaper antiretroviral drugs for HIV patients in developing countries. The deal was set up between Clinton and two Indian manufacturers of generic drugs. The reduced prices will be available in 66...

  • Hanging in the balance. Boyd, Stephanie // New Internationalist;Dec2004, Issue 374, p20 

    Focuses on the effects of various trade agreements on the availability of antiretroviral drugs in Peru. Establishment of intellectual property rules; Affordability on the costs of the pharmaceutical products; Efforts of the HIV patients to demand for free generic drugs to the government.

  • Phannacokinetics of lamivudine & stavudine in generic fixed-dose combinations in HIV-1 infected adults in India. Kumar, A. K. Hemanth; Ramachandran, Geetha; Rajasekaran, S.; Padmapriyadarsini, C.; Narendran, G.; Subramanyam, S. Anitha Sudha; Kumaraswami, V.; Swaminathan, Soumya // Indian Journal of Medical Research;Oct2009, Vol. 130 Issue 4, p451 

    Background & objectives: Antiretroviral drug concentrations are important determinants of clinical response to a drug accounting for both toxicity and efficacy. Several factors such as age, ethnicity, body weight and patients' immune status may influence antiretroviral drug concentrations. The...

  • WHO's use of generic antiretrovirals needs support.  // PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p2 

    Presents information on a program implemented by the World Health Organization to increase access to antiretrovirals for HIV-infected individuals in developing countries. Efforts to prove the bioequivalence of generic and brand-name antiretrovirals; Criticism of various international agencies...

  • Perception of Antiretroviral Generic Medicines: One-Day Survey of HIV-Infected Patients and Their Physicians in France. Jacomet, Christine; Allavena, Clotilde; Peyrol, Fleur; Pereira, Bruno; Joubert, Laurence Morand; Bagheri, Haleh; Cotte, Laurent; Garaffo, Rodolphe; Gerbaud, Laurent; Dellamonica, Pierre // PLoS ONE;Feb2015, Vol. 10 Issue 2, p1 

    Background: In the interest of cost effectiveness, switching antiretroviral brand name medications to generics is recommended in France since 2013. The study objective was to evaluate the perception of generics per se and antiretroviral generics in HIV-infected patients and their hospital...

  • Antiretroviral prices too high, inconsistent, says study.  // PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p9 

    Discusses research being done on the cost of antiretrovirals in the U.S. Reference to a study by F. Pascual and colleagues, presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment on July 2005; Price range of antiretrovirals per patient.

  • Patents versus Patients? Antiretroviral Therapy in India. Havlir, Diane V.; Hammer, Scott M. // New England Journal of Medicine;8/25/2005, Vol. 353 Issue 8, p749 

    Offers a discussion about the availability and affordability of antiretroviral therapy in India. Report that the president of India issued a patent-amendment ordinance requiring 20-year patents on all new medications; Objections of advocacy groups for patients with HIV infection; Obstacles for...

  • Cheaper drugs for HIV patients in developing countries.  // PharmacoEconomics & Outcomes News;8/22/2009, Issue 585, p10 

    The article reports on the agreements announced by former U.S. president Bill Clinton which would enable affordable drugs for HIV patients in developing countries. The first agreement covers four antiretrovirals from Mylan and Matrix. The cost of the antiretrovirals will be reduced. The second...

  • Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort. Stoll, Matthias; Kollan, Christian; Bergmann, Frank; Bogner, Johannes; Faetkenheuer, Gerd; Fritzsche, Carlos; Hoeper, Kirsten; Horst, Heinz-August; Lunzen, Jan van; Plettenberg, Andreas; Reuter, Stefan; Rockstroh, Jürgen; Stellbrink, Hans-Jürgen; Hamouda, Osamah; Bartmeyer, Barbara // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Background/Aim of the Study: The study aimed to determine the cost impacts of antiretroviral drugs by analysing a longterm follow-up of direct costs for combined antiretroviral therapy, cART,-regimens in the nationwide long-term observational multi-centre German HIV ClinSurv Cohort. The second...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics